ABT Jan 2026 110.000 call
| Previous Close | 13.40 |
| Open | 13.40 |
| Bid | 13.10 |
| Ask | 13.45 |
| Strike | 110.00 |
| Expire Date | 2026-01-16 |
| Day's Range | 13.40 - 13.40 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 252 |
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
ACCESSWIREIt's Draft Day: Damar Hamlin Helps Build the Abbott HeartMates Team
NORTHAMPTON, MA / ACCESSWIRE / April 23, 2024 / Abbott Eleven new HeartMates with 11 inspiring stories recognized at Abbott HeartMates Draft Day event in NYC. Abbott Just a week before the pro football draft, Abbott held a high-profile draft day experience ...
ZacksInvestors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
